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Abstract
Background: It is known that amyloid-b peptide (Ab) plays a pivotal role in the pathogenesis of Alzheimer’s
disease (AD). Interaction between Ab and the receptor for advanced glycation end products (RAGE) has been
implicated in neuronal degeneration associated with this disease. Pinocembrin, a flavonoid abundant in propolis,
has been reported to possess numerous biological activities beneficial to health. Our previous studies have
demonstrated that pinocembrin has neuroprotective effects on ischemic and vascular dementia in animal models.
It has been approved by the State Food and Drug Administration of China for clinical use in stroke patients.
Against this background, we investigated the effects of pinocembrin on cognitive function and neuronal
protection against Ab-induced toxicity and explored its potential mechanism.
Methods: Mice received an intracerebroventricular fusion of Ab25-35. Pinocembrin was administrated orally at 20
mg/kg/day and 40 mg/kg/day for 8 days. Behavioral performance, cerebral cortex neuropil ultrastructure, neuronal
degeneration and RAGE expression were assessed. Further, a RAGE-overexpressing cell model and an AD cell
model were used for investigating the mechanisms of pinocembrin. The mechanisms underlying the efficacy of
pinocembrin were conducted on target action, mitochondrial function and potential signal transduction using
fluorescence-based multiparametric technologies on a high-content analysis platform.
Results: Our results showed that oral administration of pinocembrin improved cognitive function, preserved the
ultrastructural neuropil and decreased neurodegeneration of the cerebral cortex in Ab25-35-treated mice.
Pinocembrin did not have a significant effect on inhibiting Ab1-42 production and scavenging intracellular reactive
oxygen species (ROS). However, pinocembrin significantly inhibited the upregulation of RAGE transcripts and
protein expression both in vivo and in vitro, and also markedly depressed the activation of p38 mitogen-activated
protein kinase (MAPK)-MAPKAP kinase-2 (MK2)-heat shock protein 27 (HSP27) and stress-activated protein kinase
(SAPK)/c-Jun N-terminal kinase (JNK)-c-Jun pathways and the downstream nuclear factor B (NFB) inflammatory
response subsequent to Ab-RAGE interaction. In addition, pinocembrin significantly alleviated mitochondrial
dysfunction through improving mitochondrial membrane potential and inhibiting mitochondrial oxidative stress,
and regulated mitochondrion-mediated apoptosis by restoration of B cell lymphoma 2 (Bcl-2) and cytochrome c
and inactivation of caspase 3 and caspase 9.
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Conclusions: Pinocembrin was shown to infer cognitive improvement and neuronal protection in AD models. The
mechanisms of action of the compound were illustrated on RAGE-dependent transduction inhibition and
mitochondrion protection. It appears to be a promising candidate for the prevention and therapy of AD.
Keywords: Alzheimer’s disease, amyloid-β peptide, apoptosis, pinocembrin, receptor for advanced glycation end
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Background
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease characterized by the presence of senile pla-
ques, intracellular neurofibrillary tangles and neuronal loss
[1]. Amyloid-b peptide (Ab) is found in extracellular senile
plaque cores and is recognized as one of the vital neuro-
pathological hallmarks of AD. Although the exact
mechanism of Ab-induced cell damage is unclear, multiple
molecular pathways resulting in cell death are involved in
vulnerable neuronal populations [2,3]. Surrounding the
amyloid plaques, there is an apparent chronic progressive
inflammatory response in neuronal cells [4]. Cytoplasmic
blebbing, mitochondrial calcium dyshomeostasis, cyto-
chrome c release, chromatin condensation, nuclear
damage, and DNA fragmentation can also be activated
locally following exposure to Ab [5]. Increased intracellu-
lar Ab levels could further facilitate opening of the mito-
chondrial permeability transition pores [6]. This indicates
that Ab can directly disrupt mitochondrial function,
reduce energy metabolism and contribute to the mito-
chondrion-dependent apoptosis.
Ab is a pleiotropic peptide and is capable of binding to
the receptors at several different membrane locations [7].
The receptor for advanced glycation end products
(RAGE), a multiligand receptor of the immunoglobulin
superfamily of cell surface molecules [8-10], possesses a
cell surface binding site for Ab peptides [7] and is
expressed at higher levels when stimulated by excessive
amounts of Ab [11,12]. RAGE has been extensively studied
for its role in migration and differentiation of neuronal
cells during development, perturbation of neuronal cells
by Ab and for its role in the inflammatory response
[11,13-15]. The wild-type RAGE transgene targeted to
neurons in the transgenic AD mouse model that expressed
mutant human amyloid precursor protein (APP) has been
shown to accelerate Ab-mediated neuronal perturbation
[16,17]. In the same way, administration of Ab has been
shown to be cerebrotoxic, and RAGE was also robustly
expressed throughout the adult rat brain in neurons and
glia in ischemic pathology [18]. As a consequence of Ab-
RAGE interaction, activation of p38 mitogen-activated
protein kinases (p38MAPK), stress-activated protein
kinase or c-Jun N-terminal kinase (SAPK/JNK), and
nuclear factor B (NFB) signaling transduction was seen
in synaptic failure of sporadic AD cybrids [15]. Therefore,
Ab-RAGE is known to be a key mediator of neuronal
damage in AD, as well as a contributor to stroke pathology
through dependent upregulation of inflammatory cyto-
kines and NFB [19].
Pinocembrin (5,7-dihydroxyflavanone; Figure 1A) is a
natural flavonoid found at high concentration in propolis.
It has been extracted as a pure compound from propolis,
and subsequently pinocembrin was synthesized and
approved by the State Food and Drug Administration
(SFDA) of China for stroke clinical trials in 2008. This
compound is well metabolized and can circulate in the
body after oral administration [20]. In particular, it is able
to pass through the blood-brain barrier (BBB) in a passive
transport process partly conducted by P-glycoprotein [21].
Our previous studies have showed that pinocembrin
reduced glutamate-induced SH-SY5Y cell injury, protected
primary cortical neurons against oxygen-glucose depriva-
tion/reoxygenation injury [22,23], and reduced the area of
cerebral infarct [22,24,25]. Moreover, pinocembrin had
potent neuroprotective effects by improving mitochondrial
function [22,26], decreasing oxidative damage [22-24],
reducing neuronal apoptosis [22,23], and inhibiting
inflammatory responses [22] in middle cerebral artery
occlusion rat models. Recently, we found that pinocembrin
alleviated learning and memory deficits in a vascular
dementia rat model through mitochondrial protection
[27], which suggests that pinocembrin has potential thera-
peutic effects for cognitive impairment.
Even though experimental evidence suggests that pino-
cembrin exerts neuroprotective effects and improves cog-
nitive function, no pre-existing study has reported the
exact molecular mechanism of this compound. Thus, as a
part of our ongoing evaluating program to explore the
potential mechanisms, we examined the effects of pino-
cembrin on improving cognitive impairment in mice
induced by intracerebroventricular infusion of Ab25-35.
Furthermore, we investigated the mechanisms underlying
the efficacy of the compound on target action, mitochon-
drial function and potential signal transduction in differ-
ent cell models using fluorescence-based multiparametric
technologies with a high-content analysis platform.
Methods
Animals and treatment
Pinocembrin (high performance liquid chromatography
(HPLC) purity >98%) was synthesized by the Department
of Medical Synthetic Chemistry, Institute of Materia
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Medica, Beijing, P R China. Ab25-35 and Ab1-42 were pur-
chased from Sigma Chemical Co (St Louis, MO, USA).
Ab25-35 was dissolved in sterile saline (1 mM) and aggre-
gated by incubation at 37°C for 7 days before use.
Male Kunming mice, 25 to 30 g, were provided by the
Animal Breeding Center of the Chinese Academy of Medi-
cal Sciences. Mice were housed five per cage and accli-
mated to standard laboratory conditions (12 h light, 12 h
dark cycle) with free access to mouse chow and water.
The animal breeding and experiments were conducted in
accordance with institutional guidelines and ethics and
approved by the Laboratories Institutional Animal Care
and Use Committee of Chinese Academy of Medical
Sciences and Peking Union Medical College.
Mice were anesthetized with 50 mg/kg sodium pento-
barbital (Sigma, St. Louis, MO, USA) and placed in a
stereotaxic instrument (RWD Life Science, Shenzhen,
China). The aggregated Ab25-35 was injected into the right
lateral ventricle with the following coordinates: -0.5 mm
anterior/posterior, +1.0 mm medial/lateral and -2.5 mm
dorsal/ventral from Bregma (10 nmol in 3 μl of saline per
injection). Sham animals were injected in an identical
manner with the same amount of sterile saline.
A total of 48 mice were used, allocated to one of four
groups the day after sterile saline or Ab25-35 injection:
sham group, Ab25-35-treated group, pinocembrin 20 mg/
kg group, and pinocembrin 40 mg/kg group (12 mice in
each group). Pinocembrin was dissolved in distilled water
containing 20% hydroxypropyl-b-cyclodextrin (Sigma, St
Louis, MO, USA) at a concentration of 10 mg/ml, and was
administered by oral gavage once a day continuously for 8
days. The sham group and Ab25-35-treated group received
oral gavage in the same manner using distilled water con-
taining 20% hydroxypropyl-b-cyclodextrin without pino-
cembrin. After behavioral testing was completed, half the
mice in each group were anaesthetized and killed by
Figure 1 Chemical structure of pinocembrin and the effect of pinocembrin on the behavior of amyloid-b peptide (Ab)25-35-treated
mice in Morris water maze (MWM). (A) Structure of pinocembrin. (B) Comparison of latency to platform during 5 days of training in MWM.
Acquisition training was initiated on the third day of pinocembrin oral administration (day 1 for MWM test). Daily training consisted of four trials
in which the mouse was placed in the water from four random starting positions (north, east, south, and west) and the escape latency onto the
platform was recorded. Data are presented as the mean ± SEM. In all 12 mice were tested per group. (C) Pinocembrin increased the percentage
of time the mouse stayed in the target quadrant in the probe test. ***P < 0.01 vs sham, ##P < 0.01, ###P < 0.001 vs Ab25-35. Data are presented as
the mean ± SEM, n = 12 mice per group. (D) Pinocembrin increased the numbers of crossings where the platform had been located in the
probe test. ***P < 0.01 vs sham, ##P < 0.01 vs Ab25-35. Data are presented as the mean ± SEM, n = 12 mice per group.
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decapitation. The brains were quickly dissected and then
snap frozen in liquid nitrogen. The brains were stored at
-80°C before analysis. The other mice in each group were
anaesthetized and perfused with 0.9% saline (Beijing Che-
mical Works, Beijing, China) and 4% paraformaldehyde
(pH 7.40~7.50; Beijing Chemical Works, Beijing, China)
from the left ventricle of heart. The division of mice into
treatment groups and the selection of mice to be killed
within each group were both performed randomly.
Morris water maze (MWM) performance
The MWM task was used to evaluate the learning and
memory changes in mice [28]. Briefly, maze training
began on the third day of pinocembrin administration. In
each trial, the time required to escape onto the hidden
platform was recorded as escape latency. Mice were
trained for five consecutive days. On the ninth day of
pinocembrin treatment, a single probe trial was con-
ducted. The time the mouse stayed in the platform quad-
rant and the crossings where the platform had been
located were recorded. The treatments were continued
during the water maze task.
Transmission electron microscopy (TEM) assay
For the TEM assay, mice were anaesthetized with an
intraperitoneal injection of 45 mg/kg sodium pentobarbi-
tal (Sigma, St. Louis, MO, USA). The heart was exposed
and the left ventricle was perfused with 0.9% saline, fol-
lowed by perfusion with 4% paraformaldehyde (Beijing
Chemical Works, Beijing, China). At the end of brain
perfusion, the temporal cerebral cortices were isolated
carefully and placed in fixative [approximately 20 ml of
2.5% glutaraldehyde (Merck, Darmstadt, Germany) and
2.0% paraformaldehyde (Beijing Chemical Works, Beijing,
China) in 0.15 M cacodylate buffer (Merck, Darmstadt,
Germany)] overnight. Then, the samples were post-fixed
in 1% osmium tetroxide (Sigma, St. Louis, MO, USA),
stained in 2% uranyl acetate (Sigma, St. Louis, MO,
USA), dehydrated in ethanol (Beijing Chemical Works,
Beijing, China) and acetone (Beijing Chemical Works,
Beijing, China), and embedded in epoxy resin (Beijing
Zhongjingkeyi Technology, Beijing, China). Ultrathin sec-
tions (60 nm thick) were obtained of selected blocs of the
samples. The ultrathin sections were mounted on copper
grids (200 mesh; Beijing Zhongjingkeyi Technology, Beij-
ing, China) and double-contrasted with uranyl acetate
and lead citrate (Sigma, St. Louis, MO, USA) for exami-
nation in a LEO 906 transmission electron microscope
(Zeiss, Oberkochen, Germany) operated at 60 kV.
Fluoro-Jade B staining assay
Fluoro-Jade B (FJB; Histochem, Jefferson, AR, USA) was
used to determine neuron degeneration induced by Ab25-35
in the cerebral cortex as described previously [29,30].
Briefly, the slides were first immersed in 100% ethanol
(Beijing Chemical Works, Beijing, China), followed by 70%
ethanol and 30% ethanol. These slides were then oxidized
by soaking in 0.06% potassium permanganate (Sigma, St
Louis, MO, USA), and transferred to a 0.0004% FJB for 30
min. After washing, the slides were air dried, cleared in
xylene (Beijing Chemical Works, Beijing, China), and cov-
erslipped with a mounting medium for histological detec-
tion. The slices were examined using an Olympus IX71
fluorescent microscope (Olympus, Tokyo, Japan) with blue
excitation light and a barrier filter. Neurons undergoing
degeneration showed bright fluorescence in comparison to
the background. The number of FJB-positive neurons was
counted in a section. In the cerebral cortex regions the
number of FJB-positive neurons was calibrated as the num-
ber of neurons in 1 mm2. Cell counts were obtained by
averaging the counts from 10 sections taken from each
mouse.
RNA analysis and western blot assay
The expression of RAGE in cerebral cortex was deter-
mined by quantitative real-time polymerase chain reaction
(PCR) and western blot. Total RNA was extracted from
part of the tissues using TRIzol reagents (Invitrogen,
Carlsbad, CA, USA) and was processed directly to produce
cDNA using TaqMan reverse transcription reagents kit
(Applied Biosystems, Foster City, CA, USA). Quantitative
real-time PCR was performed on the ABI Prism 7500
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) with Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA). Mouse RAGE
primer and probe consist of forward primer, 5’-ACAGGC-
GAGGGAAGGAGGTCAAGT-3’; reverse primer, 5’-
TGGGCAGAGATGGCACAGGTCA-3’) (Genbank: L334
12). b-Actin was used as a control. Data were calculated
using the 2-ΔΔCt method and are expressed as fold increase
over the indicated controls.
Other samples of the tissues were used to determine
protein expression of RAGE. Proteins were extracted
from the pellets by using lysis buffer [50 mM Tris-HCl
(pH 7.4; Sigma, St Louis, MO, USA), 20 mM ethylenedia-
minetetra-acetic acid (EDTA; Beijing Chemical Works,
Beijing, China), 0.1% sodium dodecyl sulfate (SDS;
Sigma, St Louis, MO, USA), 100 mM NaCl (Beijing Che-
mical Works, Beijing, China), 1% NP-40 (Sigma, St Louis,
MO, USA), 0.5% sodium deoxycholate (Sigma, St Louis,
MO, USA), 50 mM sodium fluoride (Sigma, St Louis,
MO, USA), 1 mM sodium orthovanadate (Sigma, St
Louis, MO, USA), 1 mM phenylmethanesulfonylfluoride
(PMSF; Sigma, St Louis, MO, USA), 2 mM sodium pyro-
phosphate (Sigma, St Louis, MO, USA), 1 μg/ml pepsta-
tin A (Sigma, St Louis, MO, USA), 100 μg/ml leupeptin
(Sigma, St Louis, MO, USA) and one protease inhibitor
cocktail tablet (1/50 ml; Roche Molecular Biochemicals,
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Indianapolis, IN, USA)]. Samples were boiled for 3 min
before loading onto SDS-polyacrylamide gel. After electro-
phoresis, the gel was electroblotted onto polyvinylidene
difluoride membranes. Membranes were blocked in Tris-
buffered saline (TBS; Sigma, St Louis, MO, USA) with 1%
Tween-20 (TBST; Sigma, St Louis, MO, USA) and 5%
non-fat dry milk (Sigma, St Louis, MO, USA), and then
incubated with anti-RAGE (1:800, Cell Signaling Technol-
ogy, Bervely, MA, USA ) overnight at 4°C. Membranes
were washed several times with TBST prior to incubation
with Horseradish peroxidase (HRP)-conjugated secondary
antibody (1:1,000, ZSGB-Bio, Beijing, China) for 45 min at
room temperature. After subsequent washes in TBST, the
protein bands were visualized using an ECL™ detection
kit (GE Healthcare; Piscataway, NJ, USA) and exposure to
X-ray films. Relative optical densities and areas of bands
were quantified using the Image J densitometry software
(version 1.6, National Institutes of Health, Bethesda, MD,
USA). The densitometric plots of the results were normal-
ized to the intensity of the actin band.
Cell cultures, transfections and treatments
U2OS cells were firstly applied to be stably transduced
with a reporter plasmid (pEGFP-N1) encoding a strong
response region of human RAGE promoter [31] as a
RAGE-overexpressing cell model, and then coincubated
with pinocembrin in order to specifically dissect whether
there is an effect on RAGE expression U2OS cells were
grown in McCoy’s 5A medium (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal calf serum (FBS;
Gibco/Invitrogen, Grand Island, NY, USA) at 37°C in
humidified 5% CO2 air. The enhanced green fluorescent
protein (EGFP)-based plasmid encoding human RAGE
promoter was transfected into U2OS cells and the stably
expressing cells were selected by G418 resistance (Invi-
trogen, Carlsbad, CA, USA). The RAGE-overexpressing
cell model was established by using Ab1-42 to induce
RAGE transcription and trigger RAGE overexpression.
Cells were treated with 50 nM Ab1-42 for 24 h, or coin-
cubated Ab1-42 with 1.0 μM, 3.0 μM, or 10.0 μM pino-
cembrin for 24 h. The cells were then randomly divided
into five groups: (1) RAGE control group; (2) RAGE
group in the presence of 50 nM Ab1-42 for 24 h; RAGE
group in the presence of 50 nM Ab1-42 with pinocem-
brin treatment at (3) 1.0 μM, (4) 3.0 μM, and (5) 10 μM
for 24 h. After the treatment, the cells were imaged and
analyzed by a fluorescence-based Cellomics ArrayScan
high-content screening (HCS) Reader (Thermo Fisher
Scientific Cellomics, Pittsburgh, PA, USA) with the
Morphology Explorer BioApplication. The optical fields
were scanned with a 20 × objective lens to obtain a
minimum of 1,000 cells per well. The EGFP images and
fluorescent intensity were acquired using a 485/20 nm
excitation and 535/50 nm emission filters with a 600 ms
exposure time. The level of RAGE overexpression was
illustrated by the value of mean average fluorescent inten-
sity (Mean_AvgInten). Percentage of RAGE expression
inhibition was calculated using the following formula: 100
× (Ab25-35-treated Mean_AvgInten - pinocembrin-treated
Mean_AvgInten) ÷ Ab25-35-treated Mean_AvgInten.
Human neuroblastoma SH-SY5Y cells overexpressing
the Swedish mutant form of human APP (abbreviated to
‘APPsw cells’) were established as an AD cell model by
using copper to trigger the neurotoxicity of Ab. In this
model, Ab was overproduced in the cell line but had no
toxicity during cultural process in the absence of Cu2+. In
contrast, Ab-mediated neurotoxicity was shown in the
presence of Cu2+. This is an in vitro cell model for indu-
cing Ab-mediated neurotoxicity in which copper acts as a
stimulator for Ab when supplemented in culture medium.
Cells were treated with 300 μM copper (copper sulfate,
Sigma, St Louis, MO, USA) for 24 h, and then given fresh
medium containing or not 1.0 μM, 3.0 μM, and 10.0 μM
pinocembrin to incubate 24 h. Cells were randomly
divided into five groups: (1) APPsw group; (2) APPsw cells
in the presence of 300 μM copper; (3) APPsw cells in the
presence of 300 μM copper with pinocembrin treatment
at 1.0 μM; (4) 3.0 μM; (5) 10.0 μM. Subsequently, the cells
and medium were collected for detecting the effects of




inner salt) assay was used for evaluating APPsw cell via-
bility. After being treated with pinocembrin plus copper
as described above, the medium was discarded and
replaced with 100 μl of MTS solution (Promega, Madi-
son, WI, USA) according to the manufacturer’s protocol.
After incubation at 37°C for 1 h, absorbance at 490 nm
was measured on a SpectraMax Plus microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
Measurements of intracellular reactive oxygen species (ROS)
ROS in APPsw cells were measured based on the oxida-
tion of 2’,7’-dihydrodichlorofluorescein diacetate
(DCFH-DA; Sigma, St Louis, MO, USA) to 2’,7’-dichlor-
ofluorescein (DCF) [32]. DCF fluorescence intensity was
detected and analyzed by a Cellomics ArrayScan VTI
HCS Reader (Thermo Fisher Scientific Cellomics, Pitts-
burgh, PA, USA) with the Morphology Explorer BioAp-
plication. The cell images were acquired using a 485/20
nm excitation and 535/50 nm emission filters with a
300 ms exposure time. The level of intracellular ROS
was illustrated by the value of mean average fluorescent
intensity (Mean_AvgInten).
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Mitochondrial membrane potential (MMP) and superoxide
detection
The mitochondrial changes of the APPsw cells were moni-
tored using the fluorescent dyes, Rh123 and MitoSOX
Red. The former is a cell permeable cationic dye that pre-
ferentially partitions into mitochondria based on the
highly negative MMP. Depolarization of the MMP leads to
the loss of Rh123 from the mitochondrion and appears an
increased intracellular fluorescence [33]. The latter is a
mitochondrial superoxide indicator, which is chemically
targeted to mitochondria and exhibits red fluorescence
when oxidized by superoxide [34]. Rh123 (Dojindo
Laboratory, Kumamoto, Japan) and MitoSOX Red (Invi-
trogen, Carlsbad, CA, USA) were added to cell cultures to
achieve a final concentration of 10 μM and 5 μM, respec-
tively, for 30 min at 37°C after the APPsw cells were trea-
ted with pinocembrin plus copper as described above. The
nucleic acid dye Hoechst 33342 (Dojindo Laboratory,
Kumamoto, Japan) was used to identify the nucleus, and
was added at a final concentration of 10 μM 10 min before
the Rh123 and MitoSOX Red coincubation ended. Fluor-
escent images and intensities were acquired and analyzed
by a Cellomics ArrayScan VTI HCS Reader (Thermo
Fisher Scientific Cellomics, Pittsburgh, PA, USA) com-
bined with the Cell Health Profiling BioApplication Guide
provided with the BioApplication software. Hoechst
33342, Rh123 and MitoSOX Red stained images were
acquired using the 386/23 nm excitation and 460/40 nm
emission, 485/20 nm excitation and 535/50 nm emission,
and 549/15 nm excitation and 590/50 nm emission filters,
respectively.
RAGE expression analyses
The expression of RAGE in APPsw cells was determined
by quantitative real-time PCR and immunofluorescence
assay. After the APPsw cells were treated with pinocem-
brin plus copper as described above, total RNA was
extracted. The human RAGE primer and probe consisted
of forward primer, 5’-GATCCCCGTCCCACCTTCT-3’;
reverse primer, 5’-GCTACTGCTCCACCTTCTG-3’
(Genbank: NM_001206966.1).
RAGE protein expression was examined by immuno-
fluorescence assay. Briefly, cells were fixed with 4% paraf-
ormaldehyde, permeabilized with 0.3% Triton X-100
(Sigma, St Louis, MO, USA), and then blocked with 3%
bovine serum albumin (BSA; Sigma, St Louis, MO, USA)
at room temperature. Next, cells were incubated with pri-
mary anti-RAGE antibody, followed by Alexa Fluor 488
conjugated secondary antibody (Invitrogen, Carlsbad,
CA, USA). Fluorescent images and intensity were
acquired and quantified by a Cellomics ArrayScan VTI
HCS Reader (Thermo Fisher Scientific Cellomics, Pitts-
burgh, PA, USA) and the Compartmental Analysis
BioApplication Software Module. The optical fields were
scanned with a 20 × objective lens to obtain a minimum
of 1,000 cells per well. Mean average fluorescent intensity
(Mean_AvgInten) was acquired and calculated as the
value of RAGE protein expression.
MAPK signal pathways, NFB activation and apoptotic
pathway assays
The MAPK signal pathways, NFB activation and apop-
totic pathway were all detected by immunofluorescence
assay and quantified on the Cellomics ArrayScan VTI
high-content analysis platform, using fluorescence-based
multiparametric technologies to monitor cellular consti-
tuent activities in fixed cells.
The APPsw cells were subcultured in black-walled
optically clear-bottomed 96-well plates (Corning Life
Sciences, Acton, MA, USA). After being treated with
copper plus pinocembrin as described above, cells were
fixed with 4% paraformaldehyde (Beijing Chemical
Works, Beijing, China), permeabilized with 0.3% Triton
X-100 (Sigma, St. Louis, MO, USA), and then blocked
with 3% BSA (Sigma, St. Louis, MO, USA). The primary
antibody mixture containing anti-phospho-p38 (Cell Sig-
naling Technology, Bervely, MA, USA), anti-phospho-
MAPKAP kinase-2 (MK2; Cell Signaling Technology,
Bervely, MA, USA), anti-phospho-heat shock protein 27
(HSP27; Cell Signaling Technology, Bervely, MA, USA),
anti-phospho-SAPK/JNK (Cell Signaling Technology,
Bervely, MA, USA), anti-phospho-c-Jun (Cell Signaling
Technology, Bervely, MA, USA), anti-phospho-p44/42
MAPK (Cell Signaling Technology, Bervely, MA, USA),
anti-NFB p65 (Cell Signaling Technology, Bervely, MA,
USA), anti-B cell lymphoma 2 (Bcl-2; Cell Signaling
Technology, Bervely, MA, USA), or anti-cytochrome c
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) in
phosphate buffered saline (PBS, pH 7.4, 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4 · 2 H2O, 2 mM KH2PO4)
was incubated for 2 h at room temperature. Subse-
quently, cells were incubated with corresponding second-
ary antibodies for 1 h. The primary antibodies and
corresponding secondary antibodies are listed in Table 1.
High content analysis was performed on the Cellomics
ArrayScan VTI HCS Reader (Thermo Fisher Scientific Cel-
lomics, Pittsburgh, PA, USA) using the Cytoplasm to
Nucleus Translocation BioApplication [35,36]. Briefly,
images were acquired via one to three independent chan-
nels with fixed exposure times. Based on the Hoechst
nuclear stain in channel 1, a nuclear region mask was cre-
ated and used to quantify nuclear protein distribution in
the other target channels. By expanding the nuclear region
mask, while remaining within cell boundaries, a concentric
ring was generated and used as an approximation of the
cytosolic compartment. For HSP27 and apoptotic detec-
tion, cytosolic fluorescent intensity was acquired and cal-
culated as the value of protein expression. Nuclear
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intensity was monitored and used for evaluating c-Jun
activation. Cytosolic and nuclear staining intensities were
normalized to the total nuclear region and cytosolic ring
area; this allows for the quantification of protein transloca-
tion between the nucleus and cytosol for p38, MK2,
SAPK/JNK and NFB p65. The capacity of translocation
of the four proteins was illustrated by the value of Mean_-
CircRingAvgIntenDiff. Following scan completion, all data
were exported to an Excel® (Microsoft, Redmond, WA,
USA) spreadsheet using the Cellomics vHCS View soft-
ware and expressed as mean ± SEM.
Caspase 3 and caspase 9 activity assay
Measurement of activity of caspase 3 and caspase 9
(Sigma, St. Louis, MO, USA) in the APPsw cells was per-
formed using the caspase 3 and caspase 9 assay kits.
Briefly, reactions were carried out in extraction buffer
containing 200 μg of cytosolic protein extract and 40 μM
Ac-DEVD p-nitroaniline or 40 μM Ac-LEHD p-nitroani-
line. The reaction mixtures were incubated at room tem-
perature for 2 h, and the formation of p-nitroaniline was
measured at 405 nm. The concentration of p-nitroaniline
released from the substrate was calculated from the
absorbance values.
Analysis of Ab1-42 and tumor necrosis factor a (TNFa) by
enzyme-linked immunosorbent assays (ELISAs)
Contents of Ab1-42 and TNFa in culture medium of
APPsw cells were measured by ELISA assays. Quantita-
tive levels of Ab and TNFa were measured according to
the manufacturer’s instructions (Jiameinuosi Biotech,
Beijing, China). The optical density was measured at 450
nm, and values qualified from a standard curve generated
with the limits of detection of 5 pg/ml for Ab1-42 and 7
pg/ml for TNFa.
Statistics
All data are represented as the mean ± SEM. Statistical
significance was set at P < 0.05. Statistical analyses were
performed on computer using the SPSS software (Version
13.0; SPSS, Inc., Chicago, IL, USA). Treatment differences
in the escape latency in the MWM task were analyzed
using two-factor analysis of variance with repeated mea-
sures on one factor. Tukey’s post hoc test was used if the
treatment and/or the treatment × day interaction were sig-
nificant on analysis of variance (ANOVA). The other stu-
dies were analyzed using one-way ANOVA followed by an
appropriate post hoc test to analyze the difference. Each of
the in vitro experiments was repeated at least three times.
Results
Pinocembrin inhibited RAGE-induced p38MAPK and SAPK/
JNK pathways of APPsw cells, not p44/42 MAPK in the
presence of copper
Oral pinocembrin treatment ameliorated the spatial learning
and memory deficits against Ab25-35-induced toxicity
Spatial learning was initiated on the third day of pinocem-
brin treatment (day 1 for MWM test) and assessed by the
time required to find the hidden platform (escape latency).
Figure 1B shows the results of all mice during acquisition
training. Repeated-measures ANOVA revealed a signifi-
cant day effect on escape latency (F(4,176) = 8.39, P < 0.001)
within the groups, indicating that all pinocembrin-treated
mice improved their spatial learning effectively across the
5-day training period. There was also a significant treat-
ment effect (F(3,44) = 16.68; P < 0.001) on the escape
Table 1 Primary antibodies and secondary antibodies used in this study
Primary antibody Dilution Source Secondary antibody (dilution, source)
Phospho-p38 (Thr180/Tyr182) rabbit mAb 1:800 Cell Signaling Technology
(CST)
Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad,
CA, USA)
Phospho-MK2 (Thr334) rabbit mAb 1:200 CST Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad,
CA, USA)




1:400 CST Alexa Fluor 488 donkey anti-mouse (1:500, Invitrogen,
Carlsbad, CA, USA)




1:200 CST Alexa Fluor 488 donkey anti-mouse (1:500, Invitrogen,
Carlsbad, CA, USA)
Anti-NFB p65 rabbit mAb 1:200 CST Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad,
CA, USA)
Anti-Bcl-2 rabbit mAb 1:200 CST Alexa Fluor 488 donkey anti-rabbit (1:500, Invitrogen, Carlsbad,
CA, USA)
Anti-cytochrome c mouse mAb 1:400 Santa Cruz Biotechnology Alexa Fluor 550 donkey anti-mouse (1:500, Invitrogen,
Carlsbad, CA, USA)
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latency, and subsequent comparisons further suggested
that 20 mg/kg and 40 mg/kg pinocembrin treatment
reduced the escape latency in comparison to the Ab25-35
group (20 mg/kg, P< 0.01; 40 mg/kg pinocembrin, P<
0.001) during the 5-day acquisition training, which
demonstrated that pinocembrin was effective in attenuat-
ing spatial learning deficits in Ab25-35-treated mice. There
was no significance in the interactions of treatment and
days (F(12,176) = 0.85, P > 0.05).
Furthermore, we investigated the effects of pinocembrin
on spatial memory deficits. Probe trials were conducted
on the ninth day of pinocembrin treatment (day 6 for
MWM test) to assess the spatial memory. The length of
time the mouse stayed in the target quadrant and the
numbers of crossings where the platform had been located
were both recorded. As shown in Figure 1C,D, the Ab25-
35-treated mice spent significantly less time searching for
the platform in the target quadrant and showed less num-
bers of crossings where the platform had been previously
relative to the sham mice (P < 0.001, P < 0.001). However,
pinocembrin-treated mice spent more time searching in
the target quadrant as compared to the Ab25-35-treated
mice (P < 0.01, P < 0.001). Pinocembrin treatment at 40
mg/kg also increased the numbers of crossings where the
platform was located (P < 0.01). These results demon-
strated that pinocembrin improved spatial memory against
Ab25-35-induced toxicity.
Oral pinocembrin treatment protected cerebral cortex
ultrastructure against Ab25-35-induced toxicity
To further observe the morphological changes of the
cerebral cortex, selected cortex pieces were viewed
under a transmission electron microscope. The cerebral
cortices of sham mice were characterized by the normal
appearance of neurons and surrounding astrocytes (Fig-
ure 2A, a,b). Neurons (N) showed neither swelling nor
shrinkage (Figure 2A, a). Astrocytes (As) did not exhibit
any apparent signs of perivascular edema (Figure 2A, b).
The neuropil appeared compact. In the cortices of Ab25-
35-treated mice, neuronal degeneration in the cortex was
observed (Figure 2A, c,d). The cell membranes of neu-
rons were ruptured, and the cell cytoplasm showed dark
and dense granules (Figure 2A, c). The nucleolus
showed degenerative changes and the karyoplasms were
filled with dense materials (Figure 2A, c). Intracellular
vacuolation and edema of astrocytes around neurons as
well as adjacent degeneration of the neuropil were
clearly visible (Figure 2A, d). Pinocembrin treatment at
20 mg/kg and 40 mg/kg markedly attenuated neuropil
damage in the cortex. Neuronal pycnosis was relieved
(Figure 2A, e,g). The swelling of As and disintegration
of the astrocytic cytoplasm were less apparent (Figure
2A, f,h). Signs of membrane damage and vacuolation
were less apparent.
Oral pinocembrin treatment inhibited neuronal
degeneration in cerebral cortex against Ab25-35-induced
toxicity
FJB is a very useful maker for neuronal degeneration
[29]. In the sham group, FJB-positive neurons were
hardly observed in the cerebral cortex (Figure 2B, a).
However, FJB-positive neurons were dramatically
increased in the cerebral cortex of the Ab25-35 group (P
< 0.001, Figure 2B, b,e). Pinocembrin treatment signifi-
cantly inhibited neuronal degeneration in the cerebral
cortex, showing a decreased number of FJB-positive
neurons in the pinocembrin-treated groups (P < 0.05, P
< 0.001, Figure 2B, c-e). This result suggests that pino-
cembrin was effective in inhibiting the Ab25-35-induced
neuronal degeneration.
Oral pinocembrin treatment inhibit RAGE expression in
cerebral cortex against Ab25-35-induced toxicity
To assess the RAGE changes in the cerebral cortex,
transcription and protein expression were studied fol-
lowing behavioral tests. An increased fold level of RAGE
transcripts was observed in the cerebral cortex of Ab25-
35-treated mice (P < 0.001, Figure 2C). Western blot stu-
dies displayed increased RAGE protein expression in the
cerebral cortex (P < 0.001, Figure 2D), which was con-
sistent with the changes of the level of RAGE tran-
scripts. Pinocembrin treatment significantly inhibited
the upregulation of RAGE transcripts in accordance
with its protein expression in a dose-dependent manner
(P < 0.001, Figure 2C,D), suggesting that pinocembrin
was effective in inhibiting the overexpression of RAGE
in Ab25-35-treated mice.
Pinocembrin increased cell viability, but did not attenuate
Ab1-42 secretion and scavenge intracellular ROS of APPsw
cells in the presence of copper
In order to better resemble the in vivo Ab-induced neu-
rotoxicity, instead of directly using single Ab treatment,
we used a copper-treated APPsw overexpressing cell sys-
tem [32]. As shown in Figure 3A, cell viability was sig-
nificantly decreased in the presence of 300 μM copper
in APPsw cells (P < 0.001). Pinocembrin enhanced the
cell viability at 1.0 μM, 3.0 μM and 10.0 μM in a dose-
dependent manner (P < 0.01, P < 0.001, P < 0.001).
Pinocembrin did not show a significant effect in the
APPsw cells without copper treatment for 24 h.
Copper is one of the redox metals, capable of increas-
ing oxidative stress with the production of excess super-
oxide and hydroxyl radicals due to the overproduction
of Ab [37], and thus is associated with the severe redox
imbalance in this cell model [32]. Copper increased the
Ab1-42 and ROS generation by about a 4.2-fold and 3.3-
fold increase, respectively (P < 0.01, Figure 3B-D). How-
ever, pinocembrin could not significantly inhibit Ab1-42
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Figure 2 Pinocembrin protected cerebral cortex ultrastructure and inhibited receptor for advanced glycation end products (RAGE)
expression against amyloid-b peptide (Ab)25-35-induced toxicity. (A) Ultrastructural analysis of cerebral cortex against Ab25-35-induced
toxicity. (a,b) The representative area of sham mice cortex was characterized by the normal appearance of neurons, surrounding astrocytes and
neuropil. Neurons (N) showed neither swelling nor shrinkage. Astrocytes (As) did not exhibit any apparent signs of perivascular edema. The
neuropil appeared compact. (c,d) In the cortex of Ab25-35-treated mice, neurons (N) showed degenerative changes. The cell membrane was
ruptured, and the cell cytoplasm showed dark and dense granules. The nucleolus showed degenerative changes and the karyoplasm was filled
with dense materials. Astrocyte (As) foot surrounding the neuron appeared swollen, producing an area of lower tissue density. (e,f) The 40 mg/
kg pinocembrin treatment markedly attenuated damage of neuropil in the cortex. Neuronal pycnosis was relieved. The swelling of astrocytes
(As) and disintegration of astrocytic cytoplasm was less apparent. (g,h) The 20 mg/kg pinocembrin treatment also alleviated neuronal pycnosis,
and the neuropil in the treatment group appeared compact. (B) Fluoro-Jade B staining assay for cortical neuronal degeneration in Ab25-35-
infused mice. (a), sham; (b), Ab25-35; (c), 20 mg/kg pinocembrin treatment; (d), 40 mg/kg pinocembrin treatment (× 100); (e), mean number of
Fluoro-Jade B positive cells/mm2 of the cerebral cortex. Data are presented as the mean ± SEM, n = 4, ***P < 0.001 vs sham, #P < 0.05, ###P <
0.001 vs Ab25-35. (C) Quantitative real-time polymerase chain reaction (PCR) for mouse RAGE mRNA in cerebral cortex in Ab25-35-infused mice.
Data are presented as the mean ± SEM, n = 5, ***P < 0.001 vs sham, ###P < 0.001 vs Ab25-35. (D) Western blot analysis for mouse RAGE protein
in cerebral cortex in Ab25-35-infused mice. Data are presented as the mean ± SEM, n = 5, ***P < 0.001 vs sham,
###P < 0.001 vs Ab25-35.
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secretion and scavenge the ROS generation in the pre-
sent model at the each concentration, which indicated
that pinocembrin did not have a sufficient effect on
decreasing Ab1-42 secretion and ameliorating the antiox-
idative ability in APPsw cells subjected to Ab-induced
neurotoxicity triggered by copper.
Pinocembrin inhibited RAGE expression both in RAGE-
overexpression cells and APPsw cells in the presence of
copper
To further verify the expression of RAGE and the effect
of pinocembrin, we used an Ab1-42-treated RAGE over-
expressing cell model, where the RAGE expression
could be elevated by excessive amounts of Ab. Mean-
while, we also detected the levels of RAGE mRNA and
protein in an AD cell model by using copper to trigger
the neurotoxicity of Ab.
As shown in Figure 4A,B, Ab1-42 triggered the upregula-
tion of RAGE by about a 3.77-fold increase in Mean_Av-
gInten values (P < 0.001) in the present model.
Pinocembrin inhibited the overexpression of RAGE (P <
0.001). The inhibition values of pinocembrin are 59.66% ±
2.06%, 65.89% ± 1.46% and 71.51% ± 0.98% at the concen-
trations of 1.0 μM, 3.0 μM and 10.0 μM, respectively. In
addition, Ab1-42 induced RAGE transcription without any
cell viability influence due to non-significant changes on
nuclear number and fluorescent intensity in RAGE-
expressing cells for 24 h, and pinocembrin did not show
significant effects on RAGE-expressing cell numbers in
the same manner (Figure 4C,D). This phenomenon might
Figure 3 Pinocembrin restored cell viability, but did not inhibit amyloid-b peptide (Ab)1-42 secretion and scavenge intracellular
reactive oxygen species (ROS) of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP
(APPsw) in the presence of copper. (A) Neuroprotective effects of pinocembrin evaluated by MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)- 2-(4-sulfophenyl)-2H-tetrazolium, inner salt) assay. Data are expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, ##P
< 0.01, ###P < 0.001 vs copper. (B) Effects of pinocembrin on Ab1-42 secretion of APPsw cells in the presence of copper. Data are expressed as
mean ± SEM, n = 6, ***P < 0.001 vs control. (C,D) Effects of pinocembrin on intracellular ROS generation in APPsw cells in the presence of
copper. Intracellular ROS levels were determined based on the 2’,7’-dichlorofluorescein (DCF) fluorescence on the ArrayScan high-content
screening (HCS) Reader with the Morphology Explorer BioApplication. (a), APPsw group; (b), APPsw cells in the presence of 300 μM copper; (c),
APPsw cells in the present of 300 μM copper with pinocembrin treatment at 1.0 μM; (d), 3.0 μM; (e), 10.0 μM. Data are expressed as mean ±
SEM, n = 6, **P < 0.01 vs control.
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Figure 4 Pinocembrin inhibited receptor for advanced glycation end products (RAGE) expression in RAGE-overexpression cells and in
human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper. (A)
Effects of pinocembrin on RAGE expression in RAGE-overexpression cells. (B) Mean_AvgInten value of enhanced green fluorescent protein
(EGFP)-RAGE in RAGE-overexpression cells being exposed to amyloid-b peptide (Ab)1-42 for 24 h. Inhibition of RAGE expression results in changes
of Mean_AvgInten value of EGFP-RAGE. Data are expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, ###P < 0.001 vs Ab1-42. (C) Nuclear
Mean_AvgInten value in RAGE-overexpression cells cocultured with pinocembrin for 24 h. Data are expressed as mean ± SEM, n = 6. (D) Cell
numbers per 20 fields of RAGE-overexpression cells cocultured with pinocembrin for 24 h. Data are expressed as mean ± SEM, n = 6. (E) Effects
of pinocembrin on RAGE expression in APPsw cells in the presence of copper. (F) Mean_AvgInten value of EGFP-RAGE in RAGE-overexpression
cells being exposed to Ab1-42 for 24 h. Inhibition of RAGE expression results in changes of Mean_AvgInten value of EGFP-RAGE. Data are
expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, ###P < 0.001 vs copper. (G) Quantitative real-time polymerase chain reaction (PCR) for
human RAGE mRNA in APPsw cells in the presence of copper. Data are presented as the mean ± SEM, n = 6, **P < 0.01 vs control, #P < 0.05,
##P < 0.01 vs copper.
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suggest that pinocembrin has a direct inhibitory effect on
RAGE expression, probably not dependent on the prolif-
eration of the cells.
Immunofluorescence assays and quantitative real-time
PCR showed a 2.8-fold increase in Mean_AvgInten values
of RAGE expression and an eightfold increase level of
RAGE transcripts in copper-treated APPsw cells (P <
0.001, P < 0.01, Figure 4E-G). Pinocembrin treatments
significantly inhibited RAGE protein expression in accor-
dance with the downregulation of the transcripts at con-
centrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-
dependent manner (P < 0.05, P < 0.01, P < 0.001, Figure
4E-G), suggesting that pinocembrin was prominent in
inhibiting the overexpression of RAGE in copper-treated
APPsw cells.
Pinocembrin inhibited RAGE-induced p38MAPK and
SAPK/JNK pathways of APPsw cells, not p44/42 MAPK in
the presence of copper
Ab-RAGE signaling is a mediator in the phosphorylation
state of MAPKs. Total p38MAPK cellular distribution and
expression levels are thought to modulate the downstream
highly expressed substrate MK2, and subsequently HSP27.
In control cells, basal levels of phospho-p38 and phospho-
MK2 were significantly confined to the cytosolic and
nuclear compartment, showing negative and high Mean_-
CircRingAvgIntenDiff values, respectively. The down-
stream phospho-HSP27 showed correspondingly weak
staining, showing a low cytosolic Mean_AvgInten value. In
copper-treated APPsw cells, the capacity of copper to pro-
mote phospho-p38 and phospho-MK2 translocation was
illustrated by a significant increase and a remarkable
decrease in Mean_CircRingAvgIntenDiff values, respec-
tively (P < 0.001, P < 0.01, Figure 5A-C). Similarly, the
downstream phospho-HSP27 showed strong fluorescence
with a 3.74-fold increase in cytosolic Mean_AvgInten
values (P < 0.001, Figure 5A,D). Pinocembrin treatments
significantly inhibited the p38MAPK signal pathway. The
translocation of cytosolic phospho-p38 to the nucleus and
nuclear phospho-MK2 to the cytoplasm were significantly
inhibited in accordance with the downregulation of down-
stream phospho-HSP27 at the concentrations of 1.0 μM,
3.0 μM and 10.0 μM in a dose-dependent manner (P <
0.05, P < 0.01, P < 0.001, Figure 5).
As a consequence of Ab-RAGE interaction, activation of
SAPK/JNK and p44/42 MAPK pathways was also
observed. The basal level of phospho-SAPK/JNK and
phospho-p44/42 MAPK was both confined to the cytosolic
compartment, shown as negative Mean_CircRingAvgIn-
tenDiff values in control cells. In copper-treated cells,
phospho-SAPK/JNK and phospho-p44/42 MAPK translo-
cation was promoted by a significant increase in Mean_-
CircRingAvgIntenDiff values, respectively (P < 0.001,
Figure 6A,B,D). The level of phospho-c-Jun was shown by
consistent changes in Mean_AvgInten values in the
nucleus (P < 0.01, Figure 6A,C). Pinocembrin treatments
significantly inhibited the SAPK/JNK pathway. The trans-
location of cytosolic phospho-SAPK/JNK to the nucleus
and the downregulation of its downstream phospho-c-Jun
were both inhibited at the concentrations of 1.0 μM, 3.0
μM and 10.0 μM in a dose-dependent manner (P < 0.05, P
< 0.01, P < 0.001, Figure 6A-C). However pinocembrin did
not show a significant effect on phospho-p44/42 MAPK
nuclear translocation.
Pinocembrin inhibited the NFB p65 translocation and
the release of inflammatory cytokines in APPsw cells in
the presence of copper
NFB activity was analyzed by quantifying the transloca-
tion of cytosolic p65 to the nucleus. As shown in Figure
7A,B, basal p65 was mainly distributed in the cytoplasm,
and Mean_CircRingAvgIntenDiff values were negative in
control cells. The p65 translocation from the cytoplasm
to the nucleus was caused in the copper-treated cells.
Mean_CircRingAvgIntenDiff values drastically increased
from -8.21 ± 0.85 in control cells to 44.14 ± 1.21 in cop-
per-treated cells (P < 0.001, Figure 7A,B). This translo-
cation was significantly inhibited by pinocembrin
treatment. The translocation of p65 to the nucleus was
inhibited at the concentrations of 1.0 μM, 3.0 μM and
10.0 μM in a dose-dependent manner (P < 0.01, P <
0.01, P < 0.01, Figure 7A,B).
The values of TNFa in APPsw cell culture superna-
tant changed in the same way. APPsw cells increased
the generation of TNFa following copper treatment, but
the secretions were significantly attenuated by pinocem-
brin at 1.0 μM, 3.0 μM and 10.0 μM in a dose-depen-
dent manner (P < 0.05, P < 0.001, P < 0.001, Figure 7C).
Pinocembrin protected mitochondrial function and
inhibited mitochondrion-induced apoptosis
The mitochondrial function of the APPsw cells was
monitored using the fluorescent dyes Rh123 and Mito-
SOX Red. The fluorescence of Rh123 and MitoSOX Red
were evaluated by Mean_AvgInten values collected from
the respective fluorescent channels using the same opti-
cal field. After incubation with copper for 24 h, the
Mean_AvgInten values of Rh123 and MitoSOX red
increased to 59.61% and 196.17% above control cells,
respectively (P < 0.01, P < 0.001, Figure 8A-C). These
data represented a loss of MMP and a special oxidation
of mitochondria. Pinocembrin alleviated mitochondrial
dysfunction remarkably. Treatment at 1.0 μM, 3.0 μM
and 10.0 μM reduced the respective Mean_AvgInten
value in a dose-dependent manner (P < 0.05, P < 0.001,
Figure 8A-C).
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The cytoprotective effects of pinocembrin were also
confirmed by Hoechst 33342 staining. As shown in Figure
8A,D, copper-treated APPsw cells contained condensed or
fragmented nuclei with strong bright Hoechst staining (P
< 0.001). However, pinocembrin attenuated nuclear con-
densation shown as lowered nuclear Mean_AvgInten
values (P < 0.001).
Mitochondrial dysfunction, caspase-dependent toxicity,
and downstream signaling pathways are documented as
critical apoptotic events during AD processes. The release
of cytochrome c, the expression of Bcl-2, and the cytosolic
activity of caspase 3 and caspase 9 were detected as mito-
chondrial related apoptotic molecular makers. The two
formers were measured by immunofluorescence labeling
by quantifying the Mean_AvgInten values in the same
optical field. The Mean_AvgInten values of Bcl-2 saw a
significant decrease, while the values of cytochrome c saw
a two-fold increase (P < 0.001, Figure 9A-C). Pinocembrin
caused the restoration of Bcl-2 and cytochrome c (P <
0.01, P < 0.001, Figure 9A-C). Similarly, the activities of
caspase 3 and caspase 9 were both increased in APPsw
cells in the presence of copper, but they were significantly
suppressed by pinocembrin treatment (P < 0.01, P < 0.001,
Figure 9D). These restorative effects were significant at the
concentrations of 1.0 μM, 3.0 μM and 10.0 μM in a dose-
dependent manner.
Figure 5 Pinocembrin inhibited receptor for advanced glycation end products (RAGE)-induced p38 mitogen-activated protein kinase
(MAPK)-MAPKAP kinase-2 (MK2)-heat shock protein 27 (HSP27) pathway of human neuroblastoma SH-SY5Y cells overexpressing the
Swedish mutant form of human APP (APPsw) in the presence of copper. (A) Images of p38MAPK-MK2-HSP27 pathways performed by high
content analysis on the ArrayScan high-content screening (HCS) Reader using the Cytoplasm to Nucleus Translocation BioApplication. APPsw
cells were treated plus copper as described in the Methods, prior to fixation, permeabilization, Hoechst nuclear staining, and immunolabeling
with antibodies targeting phospho-p38MAPK, phospho-MK2, and phospho-HSP27. Each column reflects images collected from the respective
fluorescent channels. (B,C) Values of Mean_CircRingAvgIntenDiff describing the capacity translocation of cytosolic phospho-p38 to the nucleus
and nuclear phospho-MK2 to the cytoplasm. (D) Cytosolic Mean_AvgInten value illustrating the expression of phospho-HSP27. Data are
expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, #P < 0.05, ##P < 0.01, ###P < 0.001 vs copper.
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Discussion
There are three major findings from the present study.
First, pinocembrin, for the first time, is shown to be a pro-
mising drug candidate for the treatment of AD as it is
shown to alleviate the cognitive deficits induced by Ab25-35
intracerebroventricular infusion in mice in vivo and reduce
neuronal damage and degeneration mediated by Ab in the
presence of copper in vitro. Second, the survival signaling
pathways of the actual therapeutic value of pinocembrin
have been demonstrated through inactivation of RAGE-
dependent signaling pathways and inhibition of mitochon-
drion-mediated apoptosis against Ab-mediated neurotoxi-
city. Third, RAGE was used as a therapeutic target for
evaluation of the efficacy of compounds, and an effective
inhibitory effect of pinocembrin was illustrated, as well as
the subsequent inactivation of p38MAPK, SAPK/JNK
pathways and the downstream inflammatory response.
The toxic effects of Ab on the cholinergic system and
cognitive function are variable, due to the differences in
the sites of administration and experimental models
[38-44]. The neurotoxicity of Ab interrelated with senile
plaques in AD brains is linked to the amino acids
located in positions 25 to 35 of the full length protein
[45,46]. In order to investigate the prospective therapeu-
tic value of pinocembrin on cognitive impairment and
neuronal apoptosis in correlation with neurodegenera-
tion in AD, Ab neurotoxicity induced learning and
memory deficits and neuronal injury were established by
a single intracerebroventricular infusion of Ab25-35, an
Ab1-42-treated RAGE overexpressing cell model, and a
Figure 6 Pinocembrin inhibited receptor for advanced glycation end products (RAGE)-induced stress-activated protein kinase (SAPK)/
c-Jun N-terminal kinase (JNK) pathway, but not p44/42 mitogen-activated protein kinase (MAPK) pathway of human neuroblastoma
SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper. (A) Images of SAPK/JNK and
p44/42 MAPK pathways evaluated by high content analysis on the ArrayScan high-content screening (HCS) Reader using the Cytoplasm to
Nucleus Translocation BioApplication. (B,D) Values of Mean_CircRingAvgIntenDiff describing the capacity translocation of cytosolic phospho-JNK
and phospho-p44/42 MAPK to the nucleus. (C) Nuclear Mean_AvgInten value illustrating the expression of phospho-c-Jun. Data are expressed as
mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 vs control, #P < 0.05, ##P < 0.01, ###P < 0.001 vs copper.
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copper-treated APPsw overexpressing cell system, all of
which could well reflect Ab toxicity in an Ab-rich envir-
onment both in vivo and in vitro.
Intracerebroventricular infusion of Ab25-35 was demon-
strated to induce spatial learning and memory impair-
ment in AD animal models [41-44]. Herein, a single
intracerebroventricular injection of Ab25-35 in mice
induced significant amnesia as compared to the sterile
saline -injected sham group. This confirmed that cogni-
tive impairment was induced by Ab25-35 peptide itself,
and was not attributable to an intracerebroventricular
injection. Our results showed that pinocembrin, taken by
oral gavage of 20 mg/kg/day and 40 mg/kg/day, improved
spatial learning effectively across the 5-day acquisition
training period. The Ab25-35-administered mice after
pinocembrin treatment showed a better learning capabil-
ity in finding the hidden platform by reduction of escape
latency. In the memory probe trial, the Ab25-35-treated
mice receiving pinocembrin treatment performed much
better in searching for the target quadrant and the site
Figure 7 Pinocembrin inhibited the nuclear factor B (NFB) p65 translocation and the release of inflammatory cytokines of human
neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the presence of copper. (A) Images
of NFB p65 translocation in the same field. NFB activity was analyzed on the ArrayScan high-content screening (HCS) Reader to quantify the
translocation of cytosolic p65 to the nucleus. (B) The value of Mean_CircRingAvgIntenDiff describing the translocation capacity of cytosolic p65
to the nucleus. Data are expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, ##P < 0.01 vs copper. (C) Content of tumor necrosis factor a
(TNFa) in APPsw cell culture supernatant after being exposed to copper. Data are expressed as mean ± SEM, n = 4, ***P < 0.001 vs control, #P <
0.05, ###P < 0.001 vs copper.
Liu et al. BMC Medicine 2012, 10:105
http://www.biomedcentral.com/1741-7015/10/105
Page 15 of 21
where the platform was located as compared to the Ab25-
35-administered mice.
Cerebral histomorphological or functional anomalies
could be a sign of the pathogenesis of neurodegeneration,
accompanied by cognitive disorder in AD patients [47].
Our study further confirmed that pinocembrin preserved
the ultrastructural changes of neurons and surrounding
astrocytes in the cerebral cortex as well. Both 20 mg/kg
and 40 mg/kg pinocembrin treatment protected the neu-
ropil from Ab25-35-induced toxicity, characterized by the
relatively normal appearance of neurons and surrounding
astrocytes, without shrinkage or swelling. The immunohis-
tochemical findings from the FJB staining assay were con-
sistent with the ultrastructural results. The total number
of FJB-positive cells in the cerebral cortex showed a signif-
icant reduction after pinocembrin treatment, indicating
that pinocembrin might be effective in decreasing neuro-
degeneration and improving cerebral histomorphological
outcomes. As a result of the current study on in vivo cog-
nitive function, neuronal ultrastructural investigation and
neuronal degeneration detection, pinocembrin has been
shown to be potentially beneficial for the treatment of AD.
Figure 8 Pinocembrin protected mitochondrial function and inhibited nuclear apoptosis. (A) Fluorescent images of mitochondrial
function and nuclear changes in the same field. The mitochondria were monitored using the fluorescent dyes, Rh123 and MitoSOX Red, in
living cells. Fluorescent images and intensities were acquired and analyzed by a Cellomics ArrayScan high-content screening (HCS) Reader
combined with the Cell Health Profiling BioApplication Guide provided with the BioApplication software. (B-D) Values of Mean_AvgInten of
Rh123, MitoSOX Red and Hoechst 33342 collected from the respective fluorescent channels using the same optical field. Data are expressed as
mean ± SEM, n = 6, **P < 0.01, ***P < 0.001 vs control, #P < 0.05, ###P < 0.001 vs copper.
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Therefore, the underlying mechanism of its actual thera-
peutic value has been explored and is discussed as below.
Oxidative stress plays a critical role in AD pathogenesis.
ROS production can be largely catalyzed by transition
metals, such as copper [48,49]. The association of copper
and Ab toxicity is mainly suggested in three aspects: (1)
the effect on cell viability correlated with Ab; (2) Ab-
induced neurotoxicity relevant to oxidative stress indicated
by ROS production; and (3) the effect of copper in Ab
aggregation. Here, we detected that copper increased ROS
generation by about a 3.3-fold increase, in accordance
with Ab peptide secretion and decrease of cell viability.
However, pinocembrin did not affect Ab1-42 secretion. It
modestly and non-significantly scavenged ROS generation.
Pinocembrin belongs to the flavonoids, which are thought
to be effective in quenching free radicals [50]. Although it
showed the antioxidative activities in scavenging ROS pro-
duction and decreasing some of oxidant enzyme activity in
reducing ischemic injury [22,25], pinocembrin did not
provide sufficient antioxidant effect through scavenging
ROS generation against Ab-mediated neurotoxicity stimu-
lated by copper. Our present data suggest that pinocem-
brin may act synergistically with other mechanisms for the
treatment of AD.
Figure 9 Pinocembrin inhibited mitochondrion-induced apoptosis. (A) Fluorescent images of B cell lymphoma 2 (Bcl-2), cytochrome c and
nucleus in the same field. (B,C) Values of Mean_AvgInten of Bcl-2 and cytochrome c collected from the respective fluorescent channels using
the same optical field. Data are expressed as mean ± SEM, n = 6, ***P < 0.001 vs control, ##P < 0.01, ###P < 0.001 vs copper. (D) Activity of
caspase 3 and caspase 9 of human neuroblastoma SH-SY5Y cells overexpressing the Swedish mutant form of human APP (APPsw) in the
presence of copper. Data are expressed as mean ± SEM, n = 4, ***P < 0.001 vs control, ##P < 0.01, ###P < 0.001 vs copper.
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Evidence has indicated that APP localizes not only to the
plasma membrane, but also to the mitochondrial mem-
brane, trans-Golgi network, endoplasmic reticulum, and
lysosomal membrane [51-53]. Therefore, two potential
pathways may underlie the neurotoxicity of intraneuronal
Ab: (1) Ab secreted into extracellular space is subse-
quently taken up by neurons at the neuronal cell surface,
and causes neuronal dysfunction mainly via RAGE-depen-
dent pathway; (2) Ab produced intracellularly remains
within the neuron, and promotes toxicity to various cyto-
plasmic organoids [54]. According to the possible neuro-
toxic pathways of Ab, our following explanations for the
therapeutic mechanism of pinocembrin consist of the
above two aspects.
RAGE is a potential therapeutic target in Ab-induced
processes in AD neuropathology. Neuronal RAGE is
highly overexpressed in AD patients, and has capacity to
bind various forms of Ab at the neuronal cell surface
[12,55,56]. The neurotoxic response to Ab-RAGE corre-
lates with activation the three subfamilies of MAPKs,
p38MAPK, SAPK/JNK, and extracellular signal-regulated
kinase (ERK1/2, p44/42 MAPK), and NFB transduction.
Among these toxic transductions, p38-MK2-HSP27 and
JNK/c-Jun have been shown to play important roles in
Ab/RAGE-induced synaptic dysfunction. These two path-
ways may be triggered by RAGE/Ab as downstream sig-
naling cascades that contribute to the early phases of AD
[57-59].
Based on our in vivo and in vitro studies, one of the
explanations for the molecular mechanism of pinocem-
brin is the regulation of Ab/RAGE-mediated pathways
(Figure 10). Neuronal RAGE transcripts and protein
expression were significantly upregulated in Ab-mediated
neurotoxicity models, which is in good agreement with
previous AD animal models [56,59]. As a consequence of
RAGE overexpression and Ab-RAGE activation,
p38MAPK-MK2-HSP27 and SAPK/JNK-c-Jun cascades
were phosphorylated and activated in the copper-treated
APPsw overexpressing cell system. Pinocembrin signifi-
cantly inhibited the upregulation of RAGE transcripts in
accordance with its protein expression both in vivo and
in vitro. In the Ab1-42-treated RAGE overexpressing cell
system, an evaluating in vitro model with a strong
response region of wild-type human RAGE promoter for
Figure 10 Schematic diagram of the neuroprotective pathways of pinocembrin on amyloid-b peptide (Ab)-induced neurotoxicity.
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inducing RAGE expression in which Ab acts as a stimula-
tor when supplemented in culture medium, pinocembrin
showed a direct inhibitory effect on RAGE expression.
Thereby we confirmed that pinocembrin was effective in
inhibiting the overexpression of RAGE against Ab-
mediated toxicity, and speculate that pinocembrin may
affect RAGE transcription by interacting with the gene
promoter, affecting the regulatory factors of the gene
promoter, or stabilizing mRNAs in the mRNA processing
or post-transcriptional regulation levels. Our results
further revealed that pinocembrin markedly inhibited the
activation of p38MAPK-MK2-HSP27 and SAPK/JNK-c-
Jun pathways, accompanied by a weak and apparently
ineffective inhibitory effect on ERK1/2 activation. These
inhibitory effects of pinocembrin may be secondary to
the lowering of the Ab-RAGE interaction.
NFB activation is also a neurotoxic signaling event
subsequent to Ab-RAGE activation. RAGE-mediated
activation of NFB by Ab in the brain could lead either
to comprehensive inflammation or to signaling that
could result in apoptosis. In our in vitro study, pinocem-
brin significantly hampered NFB p65 nuclear transloca-
tion and inhibited inflammatory factor release. Based on
the present data and previous reports [22,60,61], the
anti-inflammatory effect of pinocembrin demonstrated
here might be either a direct effect independent of Ab
toxicity or a secondary effect subsequent to the Ab-
RAGE interaction (Figure 10).
Another explanation for pinocembrin promoting cog-
nitive function and preserving neuronal ultrastructure
against Ab-induced toxicity is that pinocembrin pro-
tected mitochondria and regulated mitochondrion-
mediated apoptosis (Figure 10). Mitochondria play a
pivotal role in apoptosis signaling pathways. Loss of
MMP contributes to cell death by reducing ATP pro-
duction, increasing production of ROS, and enhancing
release of deadly signal molecules from the intermem-
brane space, thereby leading to caspase-dependent toxi-
city and downstream apoptotic signaling [62]. As
discussed above, Ab also localizes to the mitochondrial
membrane and has a direct toxicity to mitochondrial
function. Further, activation of MAPKs signaling path-
ways in response to a variety of stressors such as oxida-
tive stress, also leads to neuronal apoptosis via the
mitochondria-dependent pathway [63]. According to our
study, a loss of MMP and a special oxidation of mito-
chondria were apparent in APPsw cells in the presence
of copper, coincidence with intracellular ROS overge-
neration and MAPKs activation. As previous studies
have reported, pinocembrin showed a direct protective
effect on mitochondria [22,27], and we also observed
that pinocembrin alleviated mitochondrial dysfunction
through improving mitochondrial membrane potential
and protecting mitochondria from oxidative stress.
Of the apoptotic molecular makers during the mitochon-
drion-dependent pathway, Bcl-2, localized to mitochondria,
may prevent apoptotic events by lowering the amount of
free Ca2+ and increasing the tolerance of mitochondria to
high calcium loads [64]. Once mitochondrial membrane
permeabilization is induced, cytochrome c is released,
forming an oligomeric complex with dATP and Apaf-1
[65], accompanied by recruitment of procaspase 9 and its
activation. In this study, cytochrome c, Bcl-2 and caspase 3
and caspase 9 were all were changed in APPsw cells in the
presence of copper. Pinocembrin inhibited mitochondrion-
dependent apoptosis. Nuclear condensation was also atte-
nuated by pinocembrin treatment.
Additionally, there are other molecular components
involved in apoptosis from different upstream signaling
pathways. The release of cytochrome c is tightly linked
to the presence and activation of JNK, and the JNK
mediated cytochrome c release contributing to caspase 3
activation and apoptosis onset [66,67]. In addition,
HSP27 regulates apoptosis by inhibiting the release of
cytochrome c and preventing the activation of caspase 3
[68]. Combined with this evidence, pinocembrin is also
illustrated to modulate apoptosis synergistically with the
inactivation of SAPK/JNK-c-Jun pathway.
Conclusions
With the experimental design and methodology used in
the present study, we investigated the therapeutic value of
pinocembrin in cognitive function and neuronal protection
against Ab-induced toxicity. Furthermore, we explored the
therapeutic targets for the efficacy of pinocembrin, and
demonstrated the underlying mechanisms of pinocembrin
through inhibiting RAGE-dependent signaling pathway
and regulating mitochondrion-mediated apoptosis. In
summary, pinocembrin appears to be a promising candi-
date for the prevention and therapy of Alzheimer’s disease.
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